sanofi-aventis-sa网络赛诺菲安万特;商赛诺菲安万特;赛诺菲安万特公司 网络释义 1. 赛诺菲安万特 法国母公司赛诺菲安万特(Sanofi-Aventis SA)是在去年完成收购健赞。后者是一家专注为小病人群体生产治疗遗传性疾病的 …niklus.blogspot.com|基于56个网页 2. 商赛诺菲安万特 2010年10月28日,法国制药商赛诺菲安万特(Sanofi...
The article profiles Sanofi Aventis SA, a pharmaceutical company based in Paris, France. It notes that the company engages in research, manufacturing as well as marketing of pharmaceutical products and over-the-counter drugs. Sanofi-Aventis also specializes in six therapeutic areas such as thrombosis...
Sanofi pushes scientific boundaries to develop breakthrough medicines and vaccines. We chase the miracles of science to improve people’s lives.
Sanofi-Aventis … Sanofi-Aventis … 收藏厂家 搜索全网 产品分类 西药 解热镇痛/非甾体抗炎药 商品列表: 仅显示有货
Sanofi-Aventis, French pharmaceutical company founded in 2004 through the merger of Sanofi-Synthélabo SA and a much larger French firm, Aventis. Primarily focused on the development and sale of prescription medications, Sanofi-Aventis is one of Europe’s largest pharmaceutical firms. Sanofi originated...
35,38,54,56,59-hexaoxo-7,13,28-trioxa-20,36,39,53,55,58-hexazaundecacyclo[38.14.2.23,6.214,17.219,34.18,12.123,27.129,33.141,45.010,37.046,51]hexahexaconta-3,5,8,10,12(64),14,16,23(61),24,26,29(60),30,32,41(57),42,44,46(51),47,49,62,65-henicosaene-52-carboxylic ...
Sanofi-Aventis SA 使用说明 硫酸羟氯喹片的作用与功效 类风湿关节炎,盘状和系统性红斑狼疮以及由阳光引发或加剧的皮肤病变。 硫酸羟氯喹片的用药指导 片剂为口服给予。 1. 成年人(包括老年人):首次剂量为每日400mg,分次服用... 硫酸羟氯喹片的副作用 ...
Sanofi-Aventis: 2007 Should Prove a Year of Long-Awaited Resolution on Important Growth Issues.Sanofi-Aventis: 2007 Should Prove a Year of Long-Awaited Resolution on Important Growth Issues.The article focuses on the required resolution of Sanofi-Aventis SA to its litigation and regulatory risk iss...
1.A combination comprising at least one active ingredient chosen from saredutant and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from escitalopram and pharmaceutically acceptable salts thereof. 2.The combination according to claim 1, wherein said at least ...
The article reports that Vical Inc.'s shares fall by 32% as its gene therapy with Sanofi-Aventis Group SA fails during the Phase III study in patients with... C Hollingsworth - 《Bioworld Week》 被引量: 0发表: 2010年 Aventis Finally Succumbs to Sanofi-Synthelabo's Advances Aventis which...